Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.90 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.90 |
| ▸ | ITGAL | P20701 | 20/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lifitegrast SCHEMBL22556043 | 0.95 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL13167919 | 0.95 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL29386183 | 0.95 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL15445331 | 0.95 | ITGB2 (0.92) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL29355715 | 0.95 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL31010393 | 0.95 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL2632068 | 0.95 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20711071 | 0.93 | ITGB2 (0.90) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL23422265 | 0.93 | ITGB2 (0.89) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20833718 | 0.93 | ITGB2 (0.89) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9708303-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | SARCODE BIOSCIENCE INC. (US) | 2017-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | ITGB2 10/4885ICAM1 7/4885ITGAL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.